{"schema":"hottub-news/list/v1","item_schema":"hottub-news/item/v1","count":22,"sponsored":0,"items":[{"id":"n_nxadbvbw5xbgyqvb27pa","seq":1612325,"kind":"article","title":"UK Nursing Body Dumps Israel-Linked Teva After Palestine Campaign","url":"https://www.arabtimesonline.com/news/uk-nursing-body-dumps-israel-linked-teva-after-palestine-campaign","summary":"LONDON, Oct 4: The Royal College of Nursing (RCN) has ended its commercial partnership with Teva UK, removing the Israeli pharmaceutical company's sponsorship of an upcoming nursin...","published":"2026-10-04T03:27:00Z","seen":"2026-10-04T03:45:20Z","lang":"en","source":{"id":"kite-arabtimesonline-com-89bf31","name":"arabtimesonline.com","domain":"arabtimesonline.com","outlet":{"wikidata":"Q4783255","name":"Arab Times","type":"newspaper","country":"KW","designations":["newspaper"]}},"via":"kite-arabtimesonline-com-89bf31","topics":["middle-east","latest news"],"authors":["arabtimes"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q617602","name":"Palestine","type":"place"}],"image":"https://www.arabtimesonline.com/arabtimes/uploads/images/2026/10/04/145224.webp","story":"st_mqcm3kypnpw26swwb23a","category":"health","category_p":0.63,"sentiment":"negative","tone":-0.69,"political":0.7},{"id":"n_phh6fep2w2synukjtr3q","seq":1553954,"kind":"article","title":"Teva's Xgeva Biosimilar Degevma Gets FDA Nod - Renal and Urology News","url":"https://www.renalandurologynews.com/news/fda-approves-degevma-xgeva-biosimilar","published":"2026-10-03T13:00:00Z","seen":"2026-10-03T15:40:34Z","lang":"en","source":{"id":"renalandurologynews.com","name":"renalandurologynews.com","domain":"renalandurologynews.com"},"via":"gdelt-gkg-english","topics":["economy"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q29006691","name":"Xgeva","type":"other"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"}],"story":"st_hugemj2mrvtv77fsvfpa","category":"economy-business","category_p":0.31,"category2":"health","sentiment":"positive","tone":0.11,"political":0.12},{"id":"n_euwceq7hzw5nexvpdona","seq":1520094,"kind":"article","title":"삼성바이오에피스, 테바와 신규 바이오시밀러 2종 파트너십 계약","title_en":"Samsung Bioepis, Teva sign new biosimilar partnership contracts for 2 products","url":"https://www.segye.com/newsView/20261002511511","summary":"삼성바이오에피스가 글로벌 제약사 테바 파마슈티컬 인더스트리(테바)와 면역질환 바이오시밀러 후보물질 2종에 대한 파트너십 계약을 체결했다. 이번 계약 대상은 파센라(성분명 벤라리주맙) 바이오시밀러‘SB41’과 일라리스(성분명 카나키누맙) 바이오시밀러 ‘SB44’로, 양사는 2종의 후보물질에 대한 개발 및 상업화 협력 관계를 구축하게 됐다. 이번 계약에 따라","published":"2026-10-03T09:54:06Z","seen":"2026-10-03T10:55:55Z","lang":"ko","country":"KR","source":{"id":"kite-segye-com-7df8f9","name":"segye.com","domain":"segye.com","outlet":{"wikidata":"Q624291","name":"Segye Ilbo","type":"newspaper","country":"KR","designations":["daily newspaper"]}},"via":"kite-segye-com-7df8f9","entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"story":"st_pp4a6qd4ygdk22y23o6q","category":"health","category_p":0.31,"category2":"economy-business","sentiment":"positive","tone":0.43,"political":0.05},{"id":"n_o26ozfceeufchco3u3wa","seq":1487546,"kind":"article","title":"Britain's largest nursing union drops Teva sponsorship after pro-Palestinian pressure","url":"https://www.ynetnews.com/health_science/article/h1u20zrqmx","published":"2026-10-03T06:30:00Z","seen":"2026-10-03T06:36:12Z","lang":"en","source":{"id":"ynetnews.com","name":"ynetnews.com","domain":"ynetnews.com","outlet":{"wikidata":"Q2738307","name":"Ynet","type":"website","country":"IL","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","security"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"story":"st_mqcm3kypnpw26swwb23a","category":"health","category_p":0.54,"sentiment":"negative","tone":-0.36,"political":0.62},{"id":"n_dpkkk3p76aj3om4lbweq","seq":1484638,"kind":"article","title":"최대 9억달러 베팅 통할까…테바, 뚜렛 신약서 70% 틱 개선","title_en":"Will up to $900 million bet go through... Teva, 70% tick improvement in new Tourette's drug","url":"https://www.medipana.com/news/articleView.html?idxno=418720","summary":"테바가 최대 9억달러를 걸고 확보한 소아 뚜렛증후군 신약 \\'에코피팜(ecopipam)\\'이 추가 임상분석에서 환자 약 70%의 틱 증상을 치료 시작 8주 안에 의미 있게 개선한 것으로 나타났다. 장기추적에서도 18개월까지 틱 중증도 감소 효과가 이어지면서 현재 미국 식품의약국(FDA)의 우선심사를 받고 있는 에코피팜의 허가 가능성을 뒷받침할 추가 근거가 쌓이고 있다. 2일 테바는 오는 4~8일 서울에서 열리는 국제 파킨슨병·운동장애학회(MDS)에서 발표할 에코피팜의 새로운 효능·안전성 데이터를 공개했다. 에코피팜은 뇌의 도파민 D1","published":"2026-10-03T05:41:11Z","seen":"2026-10-03T06:05:38Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최봉선 기자"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"story":"st_dpkkk3p76aj3om4lbweq","category":"economy-business","category_p":0.63,"sentiment":"positive","tone":0.54,"political":0.04},{"id":"n_snjyvxemtdm62srd3lwq","seq":1473954,"kind":"article","title":"Teva Ruling Creates Medicare Drug 'Chaos,' Full DC Circ. Told","url":"https://www.law360.com/articles/2533446","published":"2026-10-03T03:08:00Z","seen":"2026-10-03T04:19:17Z","lang":"en","source":{"id":"law360.com","name":"law360.com","domain":"law360.com","outlet":{"wikidata":"Q6502903","name":"Law360","type":"news_agency","country":"US","designations":["news agency","website"]}},"via":"gdelt-gkg-english","topics":["economy","politics"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q559392","name":"Medicare","type":"other"}],"story":"st_snjyvxemtdm62srd3lwq","category":"politics","category_p":0.37,"category2":"health","sentiment":"negative","tone":-0.63,"political":0.53},{"id":"n_lebxixt2ik5ywqaghl5q","seq":1418119,"kind":"article","title":"Federal Circuit Denies En Banc Rehearing In Teva v. Eli Lilly, Preserving Precedent For Method-of-Treatment Patent Claims","url":"https://www.mondaq.com/unitedstates/patent/1849682/federal-circuit-denies-en-banc-rehearing-in-teva-v-eli-lilly-preserving-precedent-for-method-of-treatment-patent-claims","published":"2026-10-02T19:15:00Z","seen":"2026-10-02T19:46:33Z","lang":"en","source":{"id":"mondaq.com","name":"mondaq.com","domain":"mondaq.com","outlet":{"wikidata":"Q96393761","name":"Mondaq","type":"website","country":"US","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","science","politics"],"entities":[{"id":"Q1763845","name":"United States Court of Appeals for the Federal Circuit","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q2984214","name":"Eli Lilly","type":"org"}],"story":"st_lebxixt2ik5ywqaghl5q","category":"politics","category_p":0.29,"sentiment":"neutral","tone":-0.27,"political":0.29},{"id":"n_mqcm3kypnpw26swwb23a","seq":1371248,"kind":"article","title":"World’s largest nursing union cuts ties with Israeli drugmaker Teva","url":"https://www.middleeasteye.net/news/worlds-largest-nursing-union-cuts-ties-israeli-drugmaker-teva","summary":"World’s largest nursing union cuts ties with Israeli drugmaker Teva Submitted by Elis Gjevori on Fri, 10/02/2026 - 13:39 Pro-Palestine groups hail a 'major breakthrough' after the Royal College of Nursing ends its commercial partnership with leading pharmaceutical firm Teva Teva's plant in Neot Hovav, an industrial zone south of Beersheba, Israel, on 14 December 2017 (Menahem Kahana/AFP) Off The world's largest nursing union, the Royal College of Nursing (RCN), has cut ties…","published":"2026-10-02T13:59:13Z","seen":"2026-10-02T14:55:42Z","lang":"en","country":"IL","source":{"id":"kite-middleeasteye-net-260f94","name":"middleeasteye.net","domain":"middleeasteye.net","outlet":{"wikidata":"Q18085829","name":"Middle East Eye","type":"newspaper","designations":["online newspaper"]}},"via":"kite-middleeasteye-net-260f94","topics":["middle-east"],"authors":["Elis Gjevori"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"mentions":2,"story":"st_mqcm3kypnpw26swwb23a","category":"health","category_p":0.44,"sentiment":"negative","tone":-0.26,"political":0.34},{"id":"n_e3fwbkvahfos6mdducja","seq":1343431,"kind":"article","title":"Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome","url":"https://www.standard-freeholder.com/press-releases/globe-newswire/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-treatment-for-pediatric-patients-with-tourette-syndrome","published":"2026-10-02T12:06:00Z","seen":"2026-10-02T12:41:46Z","lang":"en","source":{"id":"standard-freeholder.com","name":"standard-freeholder.com","domain":"standard-freeholder.com"},"via":"gdelt-gkg-english","topics":["economy","health","politics","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q5333851","name":"ecopipam","type":"other"},{"id":"Q191779","name":"Tourette syndrome","type":"other"}],"story":"st_k4byroqrg4osoopop5la","category":"health","category_p":0.79,"sentiment":"positive","tone":-0.13,"political":0.02},{"id":"n_my7i2bdphlmbenfb3xfa","seq":1241192,"kind":"article","title":"Teva's Degevma Wins FDA Approval, Joining a Crowded Field of Xgeva Biosimilars for Cancer That Reaches Bone","url":"https://www.medicaldaily.com/teva-degevma-xgeva-biosimilar-fda-approval-479373","summary":"Teva's Degevma, a biosimilar to Xgeva, won FDA approval for bone complications from cancer. Here's what patients should know about cost and safety.","published":"2026-10-02T00:10:14Z","seen":"2026-10-02T00:50:28Z","lang":"en","source":{"id":"kite-medicaldaily-com-05fda3","name":"medicaldaily.com","domain":"medicaldaily.com","outlet":{"wikidata":"Q69052919","name":"Medical Daily","type":"website","country":"US","designations":["website"]}},"via":"kite-medicaldaily-com-05fda3","topics":["medicine"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q29006691","name":"Xgeva","type":"other"}],"story":"st_hugemj2mrvtv77fsvfpa","category":"health","category_p":0.44,"sentiment":"positive","tone":0.6,"political":0.1},{"id":"n_lqpy3s6ikaujn74c6wbq","seq":1222006,"kind":"article","title":"삼성바이오에피스, 테바와 바이오시밀러 2종 개발·상업화 계약","title_en":"Samsung Bioepis and Teva sign contract for development and commercialization of two biosimilars","url":"https://www.bosa.co.kr/news/articleView.html?idxno=3013199","summary":"[의학신문·일간보사=김정일 기자] 삼성바이오에피스(대표이사 김경아 사장)가 글로벌 제약사 테바 파마슈티컬 인더스트리와 면역질환 바이오시밀러 후보물질 2종에 대한 파트너십 계약을 체결했다.이번 계약 대상은 파센라(성분명 벤라리주맙) 바이오시밀러 ‘SB41’과 일라리스(성분명 카나키누맙) 바이오시밀러 ‘SB44’로, 양사는 2종의 후보물질에 대한 개발 및 상업화 협력 관계를 구축하게 됐다.이번 계약에 따라 삼성바이오에피스는 개발과 규제기관 허가 및 생산을 담당하며, 테바는 미국·유럽·캐나다 시장에서 판매를 담당한다.또한, 양사는 향후","published":"2026-10-01T13:18:08Z","seen":"2026-10-01T21:35:23Z","lang":"ko","source":{"id":"kite-bosa-co-kr-134b8e","name":"bosa.co.kr","domain":"bosa.co.kr","outlet":{"wikidata":"Q20445876","name":"Q20445876","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-bosa-co-kr-134b8e","topics":["medicine","보도자료"],"authors":["김정일 기자"],"entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"story":"st_pp4a6qd4ygdk22y23o6q","category":"economy-business","category_p":0.47,"sentiment":"positive","tone":0.36,"political":0.05},{"id":"n_xlbqimqkvagdm7pegrhq","seq":1121071,"kind":"article","title":"[BioS]삼성에피스, 테바와 면역질환 '新시밀러' 2종 파트너십","title_en":"Samsung Epis and Teva partner for two new biosimilars for immune diseases","url":"https://www.etoday.co.kr/news/view/2631703","summary":"삼성바이오에피스(Samsung Bioepis)는 테바 파마슈티컬인더스트리(Teva Pharmaceutical Industries)와 면역질환 바이오시밀러...","published":"2026-10-01T09:46:00Z","seen":"2026-10-01T11:16:03Z","lang":"ko","country":"KR","source":{"id":"kite-etoday-co-kr-278ce9","name":"etoday.co.kr","domain":"rss.etoday.co.kr"},"via":"kite-etoday-co-kr-278ce9","topics":["bios"],"authors":["김성민","author"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"story":"st_pp4a6qd4ygdk22y23o6q","category":"health","category_p":0.46,"category2":"science-technology","sentiment":"neutral","tone":0.3,"political":0.06},{"id":"n_nsakil4rfxxws2bcikzq","seq":1105689,"kind":"article","title":"삼성바이오에피스, 테바와 바이오시밀러 2종 개발·판매 협력","title_en":"Samsung Bioepis, Teva, and two biosimilars development and sales cooperation","url":"https://www.medipana.com/news/articleView.html?idxno=418610","summary":"삼성바이오에피스가 글로벌 제약사 테바와 면역질환 치료제 바이오시밀러 후보물질 2종의 개발·상업화를 위한 파트너십을 체결했다. 삼성바이오에피스가 개발과 허가·생산을 맡고 테바가 미국·유럽·캐나다 판매를 담당하는 구조다. 1일 삼성바이오에피스에 따르면 이번 계약 대상은 파센라(Fasenra, 성분명 벤라리주맙) 바이오시밀러 \\'SB41\\'과 일라리스(Ilaris, 성분명 카나키누맙) 바이오시밀러 \\'SB44\\'다. 계약에 따라 삼성바이오에피스는 두 후보물질의 개발과 규제기관 허가, 생산을 담당한다. 테바는 미국과 유럽, 캐나다에서 상업화를 맡","published":"2026-10-01T09:14:57Z","seen":"2026-10-01T10:03:39Z","lang":"ko","source":{"id":"kite-cdn-medipana-com-912f9c","name":"cdn.medipana.com","domain":"cdn.medipana.com"},"via":"kite-cdn-medipana-com-912f9c","topics":["medicine","파마시안"],"authors":["최인환 기자"],"entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"story":"st_pp4a6qd4ygdk22y23o6q","category":"health","category_p":0.32,"category2":"science-technology","sentiment":"positive","tone":0.4,"political":0.04},{"id":"n_oyzqmmbaztrekne2v3lq","seq":1095837,"kind":"article","title":"Samsung Bioepis, Teva enter commercialization agreement on 6 biosimilar candidates","url":"https://www.koreatimes.co.kr/business/companies/20261001/samsung-bioepis-teva-enter-commercialization-agreement-on-6-biosimilar-candidates","summary":"Samsung Bioepis and Teva Pharmaceutical Industries have entered into an agreement on commercializing the former’s up to six potential biosimilar candidates, including two confirmed investigational candidates, the companies said Thursday. According to Samsung Bioepis, the two sides have signed a global licensing, development and commercialization agreement for the potential candidates. Of them, two confirmed investigational biosimilar candidates are SB41, referencing…","published":"2026-10-01T09:12:03Z","seen":"2026-10-01T09:14:13Z","lang":"en","source":{"id":"kite-koreatimes-co-kr-c6eccf","name":"koreatimes.co.kr","domain":"feed.koreatimes.co.kr"},"via":"kite-koreatimes-co-kr-c6eccf","topics":["asia"],"authors":["author"],"entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"image":"https://newsimg.koreatimes.co.kr/2026/10/01/6b66b216-de07-4335-86ec-d79e53883e1f.jpg","story":"st_ompw4ih7sd54osqgne6q","category":"economy-business","category_p":0.38,"category2":"science-technology","sentiment":"positive","tone":0.35,"political":0.11},{"id":"n_pwjyfix2flzdts7tzaha","seq":1096310,"kind":"article","title":"삼성바이오에피스, 테바와 바이오시밀러 2종 협력…美·캐나다·유럽 판매","title_en":"Samsung Bioepis, Teva collaborate on two biosimilars... sales in the US, Canada, Europe","url":"https://www.donga.com/news/It/article/all/20261001/134770871/1","summary":"삼성바이오에피스가 글로벌 제약사 테바와 면역질환 치료제 바이오시밀러 후보물질 2종의 개발·상업화 협력에 나선다.삼성바이오에피스는 테바 파마슈티컬 인더스트리와 파센라 바이오시밀러 ‘SB41’, 일라리스 바이오시밀러 ‘SB44’에 대한 파트너십 계약을 체결했다고 1일 밝혔다.파센라는 벤라리주맙 성분의 면역질환 치료제이며, 일라리스는 카나키누맙 성분의 치료제다.이번 계약에 따라 삼성바이오에피스는 SB41과 SB44의 개발과 규제기관 허가, 생산을 담당한다. 테바는 미국과 유럽, 캐나다 시장에서 판매를 맡는다.양사는 향후 판매 지역 확대와 후속 바이오시밀러 개발 협력에 대한 파트너십 확장 옵션에도 합의했다. 구체적인 계약 금액과 조건은 공개하지 않았다.삼성바이오에피스와 테바는 기존에도 협력 관계를 이어왔다. 지난해 미국에서 희귀질환 치료제 ‘에피스클리’를 출시했으며 최근에는 캐나다에서 안과질환 치료제 ‘오퓨비즈’ 판매 파트너십을 체결했다.김경아…","published":"2026-10-01T09:08:29Z","seen":"2026-10-01T09:14:46Z","lang":"ko","country":"KR","source":{"id":"kite-donga-com-bbfdbd","name":"donga.com","domain":"rss.donga.com"},"via":"kite-donga-com-bbfdbd","entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q16","name":"Canada","type":"place"},{"id":"Q46","name":"Europe","type":"place"}],"image":"https://dimg.donga.com/wps/NEWS/IMAGE/2026/10/01/134770857.1.jpg","story":"st_pp4a6qd4ygdk22y23o6q","category":"health","category_p":0.41,"category2":"economy-business","sentiment":"positive","tone":0.4,"political":0.04},{"id":"n_cfxa6uthpfjqvluqjxfq","seq":1108922,"kind":"article","title":"サムスンバイオエピス、テバと販売協力","title_en":"Samsung Bioepis, Teva collaborate on sales","url":"https://www.chosun.com/jp/economy-jp/2026/10/01/BH4SQRPMIBG3HLCGESQLA2QKEA","summary":"サムスンバイオエピスは1日、世界的製薬会社テバ・ファーマシューティカル・インダストリーズとバイオシミラー（バイオ医薬品の後続品）の販売協力契約を締結したと発表した。ファセンラ、イラリスのバイオシミラーを開発・市販する過程で役割を分担する計画だ。サムスンバイオエピスはファセンラ、イラリスのバイオシミラーの開発、許可、生産を担当する。テバは米国、欧州、カナダで販売を担う。ファセンラ","published":"2026-10-01T09:08:21Z","seen":"2026-10-01T10:14:36Z","lang":"ko","country":"KR","source":{"id":"kite-chosun-com-8d8927","name":"chosun.com","domain":"chosun.com","outlet":{"wikidata":"Q483924","name":"The Chosun Ilbo","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-chosun-com-8d8927","authors":["홍다영 기자(조선비즈)"],"entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"image":"https://www.chosun.com/resizer/v2/JYCZXDW3RNIJYKTGIHUEQGARGU.jpg?auth=8116334ef3dde7953afae0b7b103048f75445e7c0458d670b551cf185b94a47f&height=1333&smart=true&width=2000","story":"st_pp4a6qd4ygdk22y23o6q","category":"economy-business","category_p":0.71,"sentiment":"positive","tone":0.48,"political":0.03},{"id":"n_rh66pkqpvgu4yihibrla","seq":1108921,"kind":"article","title":"삼성바이오에피스, 테바와 바이오시밀러 판매 협력","title_en":"Samsung Bioepis, Teva collaborate on biosimilar sales","url":"https://www.chosun.com/economy/science/2026/10/01/GYZTKZBXGRTGMOBVMI4TOYJQMM","summary":"삼성바이오에피스는 글로벌 제약사 테바 파마슈티컬 인더스트리와 바이오시밀러(바이오 의약품 복제약) 판매 협력 계약을 체결했다고 1일 밝혔다. 파센라, 일라리스 바이오시밀러를 개발하고 시판하는 과정에서 역할을 분담할 계획이다. 삼성바이오에피스는 파센라, 일라리스 바이오시밀러 개발과 허가, 생산을 담당한다. 테바는 미국, 유럽, 캐나다에서 판매를 맡는다. 파센라","published":"2026-10-01T09:08:21Z","seen":"2026-10-01T10:14:36Z","lang":"ko","country":"KR","source":{"id":"kite-chosun-com-8d8927","name":"chosun.com","domain":"chosun.com","outlet":{"wikidata":"Q483924","name":"The Chosun Ilbo","type":"newspaper","country":"KR","designations":["newspaper"]}},"via":"kite-chosun-com-8d8927","authors":["홍다영 기자(조선비즈)"],"entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"image":"https://www.chosun.com/resizer/v2/JYCZXDW3RNIJYKTGIHUEQGARGU.jpg?auth=8116334ef3dde7953afae0b7b103048f75445e7c0458d670b551cf185b94a47f&height=1333&smart=true&width=2000","story":"st_pp4a6qd4ygdk22y23o6q","category":"economy-business","category_p":0.46,"category2":"health","sentiment":"positive","tone":0.47,"political":0.03},{"id":"n_yujfku4eocxu4loukuoq","seq":1106375,"kind":"article","title":"삼성바이오에피스, 테바와 파트너십 강화…시밀러 2종 협력","title_en":"Samsung Bioepis strengthens partnership with Teva...collaboration on 2 biosimilars","url":"https://www.yna.co.kr/view/AKR20261001182100017","summary":"(서울=연합뉴스) 박상현 기자 = 삼성바이오에피스가 테바 파마슈티컬 인더스트리와 바이오시밀러 분야 협력을 강화한다.","published":"2026-10-01T09:07:18Z","seen":"2026-10-01T10:05:42Z","lang":"ko","country":"KR","source":{"id":"kite-yna-co-kr-f0eb60","name":"yna.co.kr","domain":"yna.co.kr","outlet":{"wikidata":"Q333206","name":"Yonhap News Agency","type":"news_agency","country":"KR","designations":["news agency"]}},"via":"kite-yna-co-kr-f0eb60","authors":["박상현"],"entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"image":"https://img.yna.co.kr/etc/inner/KR/2026/10/01/AKR20261001182100017_01_i_P2.jpg","mentions":3,"story":"st_pp4a6qd4ygdk22y23o6q","category":"science-technology","category_p":0.36,"category2":"health","sentiment":"positive","tone":0.41,"political":0.05},{"id":"n_pp4a6qd4ygdk22y23o6q","seq":1096362,"kind":"article","title":"삼성바이오에피스, 테바와 신규 바이오시밀러 2종 파트너십 체결","title_en":"Samsung Bioepis, Teva sign new biosimilar partnership for 2 products","url":"https://www.etoday.co.kr/news/view/2631678","summary":"면역질환 치료제 바이오시밀러 후보물질 2종 개발·상업화 계약파센라 바이오시밀러 'SB41', 일라리스 바이오시밀러 'SB44' 대...","published":"2026-10-01T08:48:00Z","seen":"2026-10-01T09:14:46Z","lang":"ko","country":"KR","source":{"id":"kite-etoday-co-kr-278ce9","name":"etoday.co.kr","domain":"rss.etoday.co.kr"},"via":"kite-etoday-co-kr-278ce9","topics":["일반"],"authors":["한성주","author"],"entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"story":"st_pp4a6qd4ygdk22y23o6q","category":"health","category_p":0.32,"category2":"science-technology","sentiment":"positive","tone":0.47,"political":0.04},{"id":"n_ompw4ih7sd54osqgne6q","seq":1113948,"kind":"article","title":"Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates","url":"https://www.intelligencer.ca/press-releases/business-wire/samsung-bioepis-and-teva-expand-strategic-partnership-to-advance-up-to-six-potential-biosimilar-candidates","published":"2026-10-01T08:32:00Z","seen":"2026-10-01T10:38:45Z","lang":"en","country":"CA","source":{"id":"intelligencer.ca","name":"intelligencer.ca","domain":"intelligencer.ca","outlet":{"wikidata":"Q4883859","name":"Belleville Intelligencer","type":"magazine","country":"CA","designations":["periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business","health"],"authors":["Business Wire"],"entities":[{"id":"Q16920038","name":"SAMSUNG BIOEPIS","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"}],"story":"st_ompw4ih7sd54osqgne6q","category":"science-technology","category_p":0.49,"category2":"health","sentiment":"positive","tone":0.6,"political":0.05},{"id":"n_ibk2mq3hprshqv5c2jfq","seq":518221,"kind":"article","title":"Teva Pharmaceutical Industries Ltd: Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA (denosumab-adet), a Biosimilar to Xgeva (denosumab)","url":"https://www.finanznachrichten.de/nachrichten-2026-09/69697030-teva-pharmaceutical-industries-ltd-teva-continues-biosimilar-momentum-with-u-s-fda-approval-of-degevma-denosumab-adet-a-biosimilar-to-xgeva-deno-399.htm","published":"2026-09-28T20:37:23Z","seen":"2026-09-28T20:37:23Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["economy","disaster","science","business"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q132104170","name":"Teva Pharmaceutical Industries Ltd","type":"org"},{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q29006691","name":"Xgeva","type":"other"}],"story":"st_5lg4pxlglehciydhqhwq","category":"economy-business","category_p":0.41,"category2":"health","sentiment":"positive","tone":-0.25,"political":0.07},{"id":"n_qxioz26gep6mjfsievxa","seq":520099,"kind":"article","title":"Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)","url":"https://www.manilatimes.net/2026/09/29/tmt-newswire/globenewswire/teva-continues-biosimilar-momentum-with-us-fda-approval-of-degevma-denosumab-adet-a-biosimilar-to-xgeva-denosumab/2434492","published":"2026-09-28T20:20:00Z","seen":"2026-09-28T20:50:16Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business","disaster","health"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q204711","name":"United States Food and Drug Administration","type":"org"},{"id":"Q29006691","name":"Xgeva","type":"other"}],"story":"st_5lg4pxlglehciydhqhwq","category":"science-technology","category_p":0.43,"category2":"health","sentiment":"positive","tone":-0.2,"political":0.07}]}